# Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection

> **NCT05718609** · PHASE4 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 855 (estimated)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Rabeprazole
- **DRUG:** Colloidal Bismuth Pectin Granules
- **DRUG:** Amoxicillin
- **DRUG:** Furazolidone
- **DRUG:** Clarithromycin

## Key facts

- **NCT ID:** NCT05718609
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-06-30
- **Target enrollment:** 855 (ESTIMATED)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05718609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05718609, "Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05718609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*